Evaluation of efficacy and safety of Evolocumab 140  mg in genetically characterized He-FH patients. First experience of Genoa lipid clinic

Publication date: January 2017 Source:Nutrition, Metabolism and Cardiovascular Diseases, Volume 27, Issue 1 Author(s): G. Bruzzone, P. Lopena, G. Balleari, P. Dapino, R. Fresa, A. Pende, F. Dallegri, S. Bertolini, L. Pisciotta
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research